Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Creative collage illustration of financial business. Two businessmen shaking hands for partners agreement. Conceptual illustration of success deal, corporate ethic, connection.

Cardiovascular disease

Alnylam Unites With Tenaya in Potential $1B+ Pact To Find New Genetic Heart Disease Targets

The alliance, which pairs Tenaya’s modality agnostic target identification and validation capabilities with Alnylam’s deep experience in RNA interference therapeutics, comes during a period of resurgence for the cardiovascular space.

March 5, 2026

2 min read

Heather McKenzie

Business success idea concept as a financial pathway to succeed with 3D illustration elements.

Huntington’s disease

UniQure’s Path for Huntington’s Gene Therapy Clouded by Ethical Questions as Potential Phase 3 Looms

While the FDA appears to be adamant that uniQure conduct a sham surgery–controlled Phase 3 trial before AMT-130 can be considered for approval, experts believe there is an alternate path forward for the therapy, perhaps even based on precedent from the recent drama surrounding Moderna’s mRNA flu vaccine.

March 5, 2026

7 min read

Heather McKenzie

Washington, D.C., USA- January 13, 2020: FDA Sign at its headquarters in Washington DC. The Food and Drug Administration (FDA or USFDA) is a federal agency of the USA.

FDA

FDA’s Hoeg Reportedly Trying To Hire Friend, Fellow Antidepressant Skeptic

Adam Urato, who is currently a vaccine advisor to the CDC, is closely associated with acting CDER director Tracy Beth Høeg and is a fellow skeptic of the use of selective serotonin reuptake inhibitors during pregnancy.

March 5, 2026

2 min read

Tristan Manalac

Business decision concept with a businessman standing on a huge question mark. Symbol of the future, opportunities, planning, vision. Vector illustration

Regulatory

PepGen’s Mid-Stage Myotonic Dystrophy Study Hit With ‘Surprise’ Pause

The timing of the partial hold is “odd,” according to analysts at Stifel, who noted that the preclinical data the FDA took issue with were filed in mid-2024.

March 5, 2026

2 min read

Tristan Manalac

Modern design with a positive context, a handshake. Concept of help, support and harmony between adults. Modern art collage, trendy magazine style.

Collaboration

Roche Broadens Global Clinical Trial Footprint With $480M+ South Korea Pledge

South Korea has attracted increasing investment from the pharmaceutical industry, which is drawn to the Asian country due to its experience in antibody-drug conjugates and cell and gene therapies, according to McKinsey.

March 5, 2026

1 min read

Tristan Manalac

Insights

From Grants to Family Offices: Building a Unified Financing Strategy in Biotech

In this episode of Denatured, you’ll listen to Ram May-Ron, managing partner at FreeMind Group, and Ravi Kiron, managing director at Biopharma Strategy Advisors. We’ll be speaking about how to combine nondilutive funding and family office money into a unified strategy that gets companies through the drug development valley of death.

March 5, 2026

1 min read

Jennifer C. Smith-Parker

Illustration of open door against blue texture background

Job Trends

Keeping the Door Open: Many Would Return to Companies That Laid Them Off

Over half of biopharma professionals would work again at the companies that let them go, according to a BioSpace LinkedIn poll. Several professionals, as well as recruiting and talent acquisition experts, discuss reasons for—and a key risk of—going back.

March 5, 2026

5 min read

Angela Gabriel

Illustration of a yellow envelope on a blue background with a read warning symbol

Supply chain

FDA Sends 30 Warning Letters To Continue Clampdown on Compounded GLP-1s

Having targeted Hims & Hers last year, the FDA has issued warnings to more telehealth companies over their promotion of GLP-1 drugs used to treat diabetes and obesity. In one case, compounded products were linked with multiple ER visits.

March 4, 2026

2 min read

Nick Paul Taylor

Podcast

UniQure’s Delay, REGENXBIO’s Rejection Explained, Sarepta’s Ingram Steps Down, More

UniQure and REGENXBIO are both dealing with FDA setbacks for their respective gene therapies, as regulatory experts question the FDA’s decision-making processes; CBER director Vinay Prasad is under probe for allegedly fostering a toxic workplace; Sarepta CEO Doug Ingram is stepping down after several years of tumult at the top of the muscular dystrophy–focused company; and Eli Lilly again tops Novo Nordisk in a weight loss trial.

March 4, 2026

1 min read

Heather McKenzie

Visit website

Email Us

IN THE PRESS

Press Releases

Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer

June 2, 2025

4 min read

BioMidwest

Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings